Lurbinectedin, a chemotherapy drug, can induce nausea as a side effect. Risk factors for lurbinectedin-induced nausea can vary but may include individual susceptibility, the dosage and frequency of administration, the presence of other medications that may interact with lurbinectedin, and the overall health condition of the patient. Chemotherapy-induced nausea and vomiting (CINV) is a well-known side effect of many chemotherapy drugs, including lurbinectedin. Managing CINV is crucial in cancer treatment to improve patient quality of life and treatment adherence. Healthcare providers often use guidelines and algorithms, like those provided by MD Anderson Cancer Center, to help manage CINV effectively [3]. It is essential for healthcare professionals to assess each patient individually and consider various factors that may contribute to the risk of nausea when administering lurbinectedin or any chemotherapy drug.

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8986698/
[3] https://www.mdanderson.org/content/dam/mdanderson/documents/for-physicians/algorithms/clinical-management/clin-management-cinv-adult-web-algorithm.pdf